EDIT vs GRMN · rev $32.3M vs P/E 28, rev $6.30B
Editas Medicine Inc (EDIT) versus Garmin Ltd (GRMN) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Garmin Ltd (GRMN) is a scientific & technical instruments company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported GRMN revenue for 2024-12-28 was $6.30B. Net income was $1.41B. Revenue was up 20.4% from 2023-12-30 to 2024-12-28. GRMN currently screens at market cap $41.35B and trailing P/E 28.3.
EDIT currently screens at market cap $375.2M. GRMN currently screens at market cap $41.35B and trailing P/E 28.3.
Not investment advice. Open the EDIT and GRMN stock pages for the full models.
Not investment advice.